Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pharmaceutical care

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    321 result(s) found for: Pharmaceutical care. Displaying page 1 of 17.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-001447-12 Sponsor Protocol Number: 331-10-234 Start Date*: 2019-01-11
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo- and Active controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 years old) With Schizophr...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10039636 Schizophrenia simple LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) PL (Completed) BG (Prematurely Ended) FR (Ongoing) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-002270-48 Sponsor Protocol Number: 31-14-204 Start Date*: 2019-01-31
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Randomized, Placebo-controlled Trial to Evaluate the Long-term (ie, Maintenance) Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects with Tourette’s Disorder
    Medical condition: Tourette’s Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10044126 Tourette's disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002222-20 Sponsor Protocol Number: 331-201-00080 Start Date*: 2018-02-23
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Multicenter, Randomized, Double-blind Trial of Brexpiprazole versus Placebo for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder
    Medical condition: Treatment of Manic Episodes Associated with Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10068455 Bipolar I disorder, hypomanic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-004809-58 Sponsor Protocol Number: HEBRO-001 Start Date*: 2019-04-04
    Sponsor Name:Institute for study, research, education and therapy of vascular, heart, brain and kidney nosologies (I.N.A.K.E.N)
    Full Title: Comparative study of eplerenone-based treatment strategy versus irbesartan-based blood pressure lowering in obese hypertensive patients (HEBRO Study)
    Medical condition: Primary Hypertension and Obesity
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10020775 Hypertension arterial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003364-64 Sponsor Protocol Number: SPD405-403 Start Date*: 2007-05-08
    Sponsor Name:Shire Development Inc
    Full Title: A phase IV, open-label, multi-centre trial evaluating the conversion from standard phosphate binder therapy to Fosrenol in chronic kidney disease stage 5 patients on haemodialysis
    Medical condition: Hyperphosphataemia in patients with end-stage renal disease receiving haemodialysis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IE (Completed) BE (Completed) DK (Prematurely Ended) FR (Completed) AT (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002190-20 Sponsor Protocol Number: 331-201-00081 Start Date*: 2018-04-09
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Multicenter, Randomized, Double-blind Trial of Brexpiprazole versus Placebo for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder
    Medical condition: Treatment of Manic Episodes Associated with Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10068455 Bipolar I disorder, hypomanic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HR (Completed)
    Trial results: View results
    EudraCT Number: 2017-005153-37 Sponsor Protocol Number: LJ501-CRH04 Start Date*: 2018-07-11
    Sponsor Name:La Jolla Pharmaceutical Company
    Full Title: A Randomised, Placebo-controlled, Double-blind, Multicentre Efficacy and Safety Study of LJPC-501 in Paediatric Patients > 2 to 17 Years of Age with Catecholamine-Resistant Hypotension Associated w...
    Medical condition: Catecholamine-resistant hypotension associated with distributive shock
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) EE (Completed) LT (Prematurely Ended) FR (Completed) ES (Temporarily Halted) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-000156-18 Sponsor Protocol Number: 301OTC02 Start Date*: 2018-08-15
    Sponsor Name:Ultragenyx Pharmaceutical, Inc.
    Full Title: A Long-Term Follow-up Study to Evaluate the Safety and Efficacy of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Lat...
    Medical condition: Ornithine transcarbamylase deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10071107 Ornithine transcarbamylase deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-024595-26 Sponsor Protocol Number: 287-11-201 Start Date*: 2011-10-27
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: Phase 2 Placebo-controlled Double-blind Trial of Dasatinib Added to Gemcitabine for Subjects with Locally-advanced Pancreatic Cancer
    Medical condition: Locally-advanced Pancreatic Adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) GB (Completed) AT (Completed) DE (Completed) CZ (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002783-88 Sponsor Protocol Number: 331-201-00182 Start Date*: 2018-12-27
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A 12-week, Multicenter, Active-treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheim...
    Medical condition: Agitation Associated With Dementia of the Alzheimer's Type
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) ES (Ongoing) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2017-001459-30 Sponsor Protocol Number: 331-10-236 Start Date*: 2019-03-07
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc
    Full Title: A Long-term, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole as Maintenance Treatment in Adolescents (13-17 Years Old) With Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10039636 Schizophrenia simple LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) PL (Completed) BG (Prematurely Ended) FR (Ongoing) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005159-15 Sponsor Protocol Number: DORI-NOS-1008 Start Date*: 2012-03-05
    Sponsor Name:Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Full Title: An Open-Label, Parallel-Group Study to Evaluate the Single-Dose Pharmacokinetics and Safety of Doripenem in Pediatric Patients 3 Months to 17 Years of Age, Inclusive
    Medical condition: Bacterial infections
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2023-000224-10 Sponsor Protocol Number: PBKV.5zdnia03.08.2022 Start Date*: 2023-08-17
    Sponsor Name:The Pharmaceutical Company LEK-AM Sp. Zo.o.
    Full Title: A randomized, double-blind, placebo-controlled, multicentre study to evaluate the effect of a 12-week dose of 35 mg DHEA on quality of life in menopausal women.
    Medical condition: Menopause
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000903-17 Sponsor Protocol Number: CN138-166 Start Date*: 2005-02-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Functioning of a Treatment with Aripiprazole in a Broad Range of Schizophrenic Patients
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000176-41 Sponsor Protocol Number: 341-201-00004 Start Date*: Information not available in EudraCT
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Trial to Assess the Efficacy and Safety of Orally Administered OPS-2071 for 12 Weeks in Subjects With Crohn’s ...
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PL (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003430-25 Sponsor Protocol Number: 101HEMB02 Start Date*: 2017-05-18
    Sponsor Name:Ultragenyx Pharmaceutical, Inc.
    Full Title: A Long-Term Follow-up Study to Evaluate the Safety, Tolerability, and Efficacy of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Sever...
    Medical condition: Moderate/severe to severe hemophilia B
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060614 Hemophilia B (Factor IX) LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-003598-33 Sponsor Protocol Number: LJ401-HH01 Start Date*: 2018-04-03
    Sponsor Name:La Jolla Pharmaceutical Company
    Full Title: A Phase 2, Multi-center, Randomized, Placebo-controlled, Single-blind Study with LJPC-401 for the Treatment of Iron Overload in Adult Patients with Hereditary Hemochromatosis
    Medical condition: Hereditary Hemochromatosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-005992-10 Sponsor Protocol Number: 156-201-00307 Start Date*: Information not available in EudraCT
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than 18 years of Age with Autosomal Recessive Polycystic Kidne...
    Medical condition: Autosomal Recessive Polycystic Kidney Disease (ARPKD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036047 Polycystic kidney, autosomal recessive LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000360-42 Sponsor Protocol Number: UX001-CL302 Start Date*: 2016-08-02
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Phase 3b Open-label Extension Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients with GNE Myopathy (GNEM) or Hereditary Inclusion Body Myo...
    Medical condition: GNE Myopathy, also known as Hereditary Inclusion Body Myopathy (HIBM), Distal Myopathy with Rimmed Vacuoles (DMRV), Nonaka's disease, or quadriceps sparing myopathy (QSM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000167584 10075048 Hereditary inclusion body myopathy LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10077945 GNE myopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001539-10 Sponsor Protocol Number: UX007-CL302 Start Date*: 2022-12-27
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Randomized, Double-blind, Multicenter Study to Determine the Effect of Triheptanoin Compared with Even-chain, Medium-chain Triglycerides (MCT) on Major Clinical Events (MCEs) in Pediatric Patient...
    Medical condition: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10077951 Fatty acid oxidation disorder PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 15:05:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA